Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 2;133(5):537-41.
doi: 10.1161/CIRCULATIONAHA.115.012519.

Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer

Nirmanmoh Bhatia  1 , Marilia Santos  1 , Lee W Jones  1 , Joshua A Beckman  1 , David F Penson  1 , Alicia K Morgans  2 , Javid Moslehi  2
Affiliations
Review

Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer

Nirmanmoh Bhatia et al. Circulation. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic of hypothalamic-pituitary-gonadal axis and sites of action of anti-androgen therapies. AR: Androgen receptor, DHT: Dihydrotestosterone, GnRH: Gonadotropin releasing hormone, LH: Luteinizing hormone.
Figure 2
Figure 2
“ABCDE” algorithm for prostate cancer survivors.
Figure 3
Figure 3
Algorithm to manage patients on androgen deprivation therapy in the Cardio-Oncology clinic. ADT: Androgen Deprivation Therapy, CV: Cardiovascular, ACC/AHA: American College of Cardiology/American Heart Association, CHF:Congestive Heart Failure, ACE: Angiotensin Converting Enzyme, ADA: American Diabetes Association.
See this image and copyright information in PMC

References

    1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71. - PubMed
    1. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012;104:1335–42. - PMC - PubMed
    1. Conteduca V, Di Lorenzo G, Tartarone A, Aieta M. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol. 2013;86:42–51. - PubMed
    1. Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. Eur Urol. 2015;67:825–836. - PubMed
    1. Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N American Heart Association Council on Clinical C, Council on E, Prevention tACS and the American Urological A. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833–40. - PMC - PubMed

MeSH terms